サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1636377

膵臓がん治療・診断市場レポート：タイプ別、用途別、地域別、2025-2033年

Pancreatic Cancer Therapeutics and Diagnostics Market Report by Type (Diagnostics, Treatment), Application (Hospitals, Clinics, and Others), and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 125 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
膵臓がん治療・診断市場レポート：タイプ別、用途別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 125 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

膵臓がん治療・診断の市場の世界市場規模は2024年に45億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに80億米ドルに達し、2025年から2033年にかけて6.19%の成長率（CAGR）を示すと予測しています。急成長するヘルスケア産業、膵臓がんの有病率の上昇、膵臓がん細胞を死滅させる化学療法に対する需要の高まりは、市場を牽引する重要な要因の一つです。

膵臓がん治療・診断は、膵臓がんを診断し治療を提供するために使用される医療処置です。これらの治療・診断には、超音波検査、コンピューター断層撮影（CT）スキャン、磁気共鳴画像法（MRI）、陽電子放射断層撮影（PET）スキャンが含まれます。内視鏡超音波検査（EUS）は、超音波装置を使って腹部内から膵臓の画像を作成するものです。EUSは、膵臓の細胞の制御不能な増殖による腫瘍の位置をモニターするのに役立ちます。顕微鏡で検査するために小さな組織サンプルを採取する生検の実施にも役立ちます。また、全血球計算（CBC）、胆道閉塞のための肝酵素検査、空腹時グルコースおよび糖化ヘモグロビン（HbA1C）検査などの検査室検査も補助します。その結果、膵臓がん治療・診断は世界中の病院や専門センターで応用されています。

膵臓がん治療・診断の市場動向：

現在、老年人口の増加と大衆の過度の喫煙習慣による膵臓がんの有病率の上昇は、市場の成長を支える主要な要因の1つです。これに加えて、分子生物学、薬剤、診断技術の開発が世界中で増加しています。これは、ヘルスケア産業の隆盛とともに、現在市場の成長を後押ししています。加えて、膵臓がん細胞の増殖と分裂を阻止して死滅させる化学療法の需要が高まっていることも、市場にプラスの影響を与えています。さらに、いくつかの国の行政機関は、膵臓がんの臨床試験や化学療法と組み合わせたデオキシリボ核酸（DNA）修復阻害剤に幅広く投資しています。また、臨床段階にある薬剤を承認することで、膵臓がん治療・診断の成長を高めることにも注力しています。これとは別に、この業界で事業を展開する主要企業は、食道がんや胃食道接合部がん、膵臓がん治療のために、抗腫瘍免疫反応を促進するヒト化モノクローナル抗体を導入しています。また、BRCA1とBRCA2の変異を判定し、ゲノムの不安定性を評価することで膵臓がんを検出するキットベースの検査を開発・導入しており、これが今後数年間の市場成長に寄与すると予測されています。

本レポートで扱う主な質問

  • 世界の膵臓がん治療・診断の市場はこれまでどのように推移し、今後どのように推移するのか？
  • 膵臓がん治療・診断の市場の世界市場における促進要因、抑制要因、機会は何か？
  • 主要地域市場とは？
  • 最も魅力的な膵臓がん治療・診断市場はどの国か？
  • タイプ別の市場内訳は？
  • 膵臓がん治療・診断の市場で最も魅力的なタイプはどれか？
  • 用途別の市場内訳は？
  • 膵臓がん治療・診断の市場で最も魅力的な用途は？
  • 世界の膵臓がん治療・診断の市場の競合構造は？
  • 世界の膵臓がん治療・診断の市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の膵臓がん治療・診断市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 診断
    • 市場動向
    • 主要セグメント
      • イメージング
      • 生検
      • 超音波内視鏡
      • その他
    • 市場予測
  • 治療
    • 市場動向
    • 主要セグメント
      • 標的療法
      • 化学療法
      • 手術
      • その他
    • 市場予測

第7章 市場内訳：用途別

  • 病院
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第9章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd.
    • Immunovia AB
    • Novartis AG
    • Pfizer Inc.
図表

List of Figures

  • Figure 1: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Pancreatic Cancer Therapeutics and Diagnostics (Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Pancreatic Cancer Therapeutics and Diagnostics (Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Pancreatic Cancer Therapeutics and Diagnostics (Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Pancreatic Cancer Therapeutics and Diagnostics (Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Pancreatic Cancer Therapeutics and Diagnostics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Pancreatic Cancer Therapeutics and Diagnostics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Pancreatic Cancer Therapeutics and Diagnostics (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Pancreatic Cancer Therapeutics and Diagnostics (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Pancreatic Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Pancreatic Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: North America: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: North America: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: United States: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: United States: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Canada: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Canada: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Asia-Pacific: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Asia-Pacific: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: China: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: China: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Japan: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Japan: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: India: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: India: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: South Korea: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: South Korea: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Australia: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Australia: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Indonesia: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Indonesia: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Others: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Others: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Europe: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Europe: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Germany: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Germany: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: France: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: France: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: United Kingdom: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: United Kingdom: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Italy: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Italy: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Spain: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Spain: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Russia: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Russia: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Others: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Others: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Latin America: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Latin America: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Brazil: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Brazil: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Mexico: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Mexico: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Middle East and Africa: Pancreatic Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Middle East and Africa: Pancreatic Cancer Therapeutics and Diagnostics Market: Breakup by Country (in %), 2024
  • Figure 65: Middle East and Africa: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Global: Pancreatic Cancer Therapeutics and Diagnostics Industry: Drivers, Restraints, and Opportunities
  • Figure 67: Global: Pancreatic Cancer Therapeutics and Diagnostics Industry: Value Chain Analysis
  • Figure 68: Global: Pancreatic Cancer Therapeutics and Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Pancreatic Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Competitive Structure
  • Table 6: Global: Pancreatic Cancer Therapeutics and Diagnostics Market: Key Players
目次
Product Code: SR112025A7538

The global pancreatic cancer therapeutics and diagnostics market size reached USD 4.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.0 Billion by 2033, exhibiting a growth rate (CAGR) of 6.19% during 2025-2033. The burgeoning healthcare industry, rising prevalence of pancreatic cancer, and the escalating demand for chemotherapy to kill pancreatic cancer cells represent some of the key factors driving the market.

Pancreatic cancer therapeutics and diagnostics are medical procedures used to diagnose pancreatic cancer and provide treatment. These therapeutics and diagnostics comprise ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. They rely on an endoscopic ultrasound (EUS) that uses an ultrasound device to produce images of the pancreas from inside the abdomen. They help in monitoring the location of the tumor due to an uncontrollable growth of cells in the pancreas. They assist in performing a biopsy to remove a small sample of tissue for examination under a microscope. They also aid in laboratory investigations, such as a complete blood count (CBC), liver enzyme tests for biliary obstruction, and fasting glucose and glycated hemoglobin (HbA1C) tests. As a result, pancreatic cancer therapeutics and diagnostics find applications in hospitals and specialty centers across the globe.

Pancreatic Cancer Therapeutics and Diagnostics Market Trends:

At present, the rising prevalence of pancreatic cancer due to the increasing geriatric population and excessive smoking habits among the masses represents one of the key factors supporting the growth of the market. Besides this, there is an increase in the development of molecular biology, drugs, and diagnostic technology around the world. This, along with the thriving healthcare industry, is currently propelling the growth of the market. In addition, the escalating demand for chemotherapy to kill pancreatic cancer cells by preventing them from growing and dividing is positively influencing the market. Moreover, governing agencies of several countries are extensively investing in pancreatic cancer clinical trial testing and deoxyribonucleic acid (DNA) repair inhibitors combined with chemotherapy. They are also focusing on enhancing the growth of pancreatic cancer therapeutics and diagnostics by approving drugs in the clinical phase. Apart from this, key players operating in the industry are introducing a humanized monoclonal antibody that promotes the anti-tumor immune response for treating esophageal and gastroesophageal junction and pancreatic cancer. They are also developing and introducing kit-based testing to detect pancreatic cancer by determining BRCA1 and BRCA2 variants and assessing genomic instability, which is projected to contribute to the growth of the market in the coming years.

Key Market Segmentation:

Type Insights:

  • Diagnostics
  • Imaging
  • Biopsy
  • Endoscopic Ultrasound
  • Others
  • Treatment
  • Targeted Therapies
  • Chemotherapy
  • Surgery
  • Others

Application Insights:

  • Hospitals
  • Clinics
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for pancreatic cancer therapeutics and diagnostics. Some of the factors driving the North America pancreatic cancer therapeutics and diagnostics market included advancements in diagnostic technologies, emerging therapies and treatment options, increasing healthcare expenditure, and government initiatives and funding.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global pancreatic cancer therapeutics and diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies include AstraZeneca plc, F. Hoffmann-La Roche Ltd., Immunovia AB, Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global pancreatic cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global pancreatic cancer therapeutics and diagnostics market?
  • What are the key regional markets?
  • Which countries represent the most attractive pancreatic cancer therapeutics and diagnostics markets?
  • What is the breakup of the market based on the type?
  • Which is the most attractive type in the pancreatic cancer therapeutics and diagnostics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the pancreatic cancer therapeutics and diagnostics market?
  • What is the competitive structure of the global pancreatic cancer therapeutics and diagnostics market?
  • Who are the key players/companies in the global pancreatic cancer therapeutics and diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pancreatic Cancer Therapeutics and Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Diagnostics
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Imaging
      • 6.1.2.2 Biopsy
      • 6.1.2.3 Endoscopic Ultrasound
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Targeted Therapies
      • 6.2.2.2 Chemotherapy
      • 6.2.2.3 Surgery
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 F. Hoffmann-La Roche Ltd.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Immunovia AB
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Novartis AG
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Pfizer Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.